Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, announced on Tuesday that it has formed a strategic partnership with Chinese pharmaceutical company Qilu Pharmaceutical Group and its subsidiary Shanghai Qilu Pharmaceutical Research Center.

The agreement covers innovative drug development, leveraging Insilico's proprietary Pharma.AI platform to jointly develop small molecule inhibitors, focusing on specific targets for cardiometabolic disease management.

Insilico Medicine will use its proprietary Pharma.AI platform to focus on the design and optimisation of novel small molecules for treating metabolic diseases, while Qilu Pharmaceutical Group will be responsible for subsequent development and commercialisation procedures.

The total contract value approaches USD120m, including development and commercialisation milestone payments, as well as single-digit royalties based on net sales.